Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
August 2024—The number of laboratories performing clinical metagenomic next-generation sequencing is limited, as is the number of sample types for which it’s available, but the range of pathogens mNGS detects is wide open.
August 2024–Extended-life cryoprecipitate has several pluses: longer shelf life, preserved fibrinogen function, and low risk of bacterial contamination, among others. “The big con is cost,” said Jay Hudgins, DO, MS, director of hemostasis and thrombosis, Department of Pathology and Laboratory Medicine, Nationwide Children’s Hospital, Columbus, Ohio.
August 2024—The recently discovered VEXAS syndrome is caused by somatic mutations in the UBA1 gene arising in bone marrow stem cells. VEXAS (vacuoles, E1-ubiquitin-activating enzyme, X-linked, autoinflammatory, somatic) syndrome was discovered when National Institutes of Health researchers identified deleterious mutations in ubiquitin-related genes. In a retrospective observational study published last year, Beck, et al., evaluated UBA1 variants in exome data from the Geisinger MyCode Community Health Initiative, a health-system-based cohort of patients who provide samples for broad research use. Clinical phenotypes were determined from Geisinger EHR data spanning four to 25 years. UBA1 variants were found in one in 13,591 unrelated individuals, one in 4,269 men older than 50, and one in 26,238 women older than 50.
August 2024—Digital pathology, FDA oversight of laboratory-developed tests, and the workforce shortage took center stage when CAP TODAY publisher Bob McGonnagle convened a roundtable online to talk about anatomic pathology laboratories. The shortage of pathologists, in particular, “is even greater than one might realize because of generational expectations around work-life balance,” said Andrew Bellizzi, MD, who applauds such balance but notes its significance. Their June 18 conversation follows.
August 2024—Case. A 58-year-old female patient undergoes robotic endobronchial ultrasound-guided fine-needle aspiration for a peripherally located right upper lobe stellate-shaped lung lesion with ground-glass opacification. Rapid onsite evaluation (ROSE) assessments were adequate on four Diff-Quik (DQ) smears that were prepared for evaluation. One slide was cover-slipped for diagnostic purposes and the remaining slides were retained, uncovered. The cytopathologist requested additional material for further ancillary studies. The needle was rinsed in CytoLyt solution used to prepare a cell block from the cell pellet, and the residual supernatant was stored (at -80°C) for possible future molecular studies. The cell block cellularity was adequate, and the malignant cell population represented 50 percent of the sampled cells.
August 2024—The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) is a widely endorsed and increasingly adopted standardized reporting system for salivary gland fine-needle aspiration biopsy specimens. The inaugural edition published in 2018 was inspired by the Bethesda cervicovaginal and thyroid reporting systems. The MSRSGC sought to facilitate clear and consistent communication between pathologists and the clinical team, thereby enhancing patient-centered decision-making and therapeutic interventions and assisting inter- and intralaboratory comparisons.
August 2024—Two to five percent of pancreatic tumors are pancreatic neuroendocrine neoplasms, of which more than 90 percent are well-differentiated pancreatic neuroendocrine tumors (PanNETs). The current World Health Organization classification stratifies PanNETs into three histological grades based on mitotic count and Ki-67 proliferation index. Low-grade PanNETs (grades one and two) are morphologically indistinguishable and have characteristic neuroendocrine cytomorphologic features: a dispersed/loosely cohesive smear pattern composed of small-to-medium monomorphic cells with occasional plasmacytoid appearance; amphophilic, granular, or vacuolated cytoplasm; round nuclei; and coarse salt-and-pepper chromatin.
Charna Albert May 2024—In a time of wellness testing and high rates of levothyroxine prescribing for hypothyroidism, it may also be time to rethink TSH test result interpretation. Laboratory testing is more accessible now than it used to be and patients are more involved in their own care. “You’re trying to give the patient access and ability to take care of their own health. But the double-edged sword is you can start over-ordering things, and the way we’ve designed lab
July 2024—Like a long-awaited second act, the FDA’s final rule regulating laboratory-developed tests as medical devices took the stage this spring. As with any FDA performance, this one opened to mixed reviews.
The spring curtain-raising followed the earlier proposed rule from last October, which drew some 6,500 responses during the public comment period. If that was an out-of-town tryout, no one quite knew what to expect from the rewrite, or if there would even be one.
As it turns out, there were indeed changes, but they didn’t necessarily bring clarity. As Jane Pine Wood, counsel for McDonald Hopkins, puts it, the final rule “certainly raised a whole lot more questions than it answered.”
The rule calls for a four-year, five-stage phaseout policy with the FDA enacting greater oversight of in vitro diagnostic products that are offered as LDTs.
Stage one, beginning on May 6, 2025, calls for labs to comply with medical device reporting requirements, correction and removal reporting requirements, and quality system requirements regarding complaint files.
July 2024—With the Food and Drug Administration approval in May of two HPV self-collection devices for use in clinic settings, physicians in and out of the laboratory are optimistic the approach can reach underscreened patients, even if FDA approval is only a first step.
